Failure Patterns by PSMA PET for Recurrent Prostate Cancer after Prostatectomy and Salvage Radiation - 30/11/22

Abstract |
Objective |
To characterize patterns of failure using prostate-specific membrane antigen positron emission tomography (PSMA PET) after radical prostatectomy (RP) and salvage radiotherapy (SRT).
Methods |
Patients with rising PSA post-RP+SRT underwent 68Ga‐HBED‐iPSMA PET/CT on a single-arm, prospective imaging trial (NCT03204123). Scans were centrally reviewed with pattern-of-failure analysis by involved site. Positive scans were classified using 3 failure categories: pelvic nodal, extra-pelvic nodal or distant non-nodal. Associations with failure categories were analyzed using cumulative incidence and generalized logits regression.
Results |
We included 133 men who received SRT a median of 20 months post-RP; 56% received SRT to the prostatic fossa alone, while 44% received pelvic SRT. PSMA PET/CT was performed a median of 48 months post-SRT. Overall, 31% of PSMA PET/CT scans were negative, 2% equivocal and 67% had at least 1 positive site. Scan detection was significantly associated with PSA level prior to PSMA PET/CT. Analysis of 89 positive scans demonstrated pelvic nodal (53%) was the most common relapse and fossa relapse was low (9%). Overall, positive scans were pelvic (n = 35, 26%), extra-pelvic nodal (n = 26, 20%) or distant non-nodal failure (n = 28, 21%), and 70% of positive scans were oligorecurrent. We observed similar cumulative incidence for all failure categories and relatively few clinicodemographic associations. Men treated with pelvic SRT had reduced odds of pelvic failure versus exclusive fossa treatment.
Conclusion |
Pelvic, extra-pelvic nodal, and distant non-nodal failures occur with similar incidence post-SRT. Regional nodal relapse is relatively common, especially with fossa-only SRT. A high oligorecurrence rate suggests a potentially important role for PSMA-guided focal therapies.
Le texte complet de cet article est disponible en PDF.Plan
| Disclosure/COI: BI has received an honorarium from GT Medical Technologies. EO, EH, SL, ZZ, RG, DG and MK report no commercial interests or potential conflicts of interest. LP reports consulting agreements with Blackstone Investments / Clarus Ventures, Third Rock Ventures, Galera Therapeutics, Dynamo Therapeutics, Myst Therapeutics, Monte Rosa Therapeutics, Best Doctors / Teladoc Inc and equity ownership in Schrödinger, Novavax and Clovis Oncology. BM reports that he is a Member of the Medical Advisory Board, Radiation Oncology for eviCore Healthcare. SM reports research funding from Janssen and Genentech and honoraria from Astra-Zeneca. MZ receives research funding from Ferring Pharmaceuticals, Novartis, and Bayer. |
|
| Funding: This research was funded in part through the National Institute of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748. |
|
| Data Sharing: Research data are stored in an institutional repository and will be shared upon request to the corresponding author. |
Vol 170
P. 146-153 - décembre 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
